Bionano: OGM Studies Reveal High-Risk Genomic Alterations Missed By Standard Cytogenetics

Bionano Genomics said three independently authored, peer-reviewed studies found its optical genome mapping technology can identify clinically significant structural genomic alterations in myelodysplastic syndromes and acute myeloid leukemia. The findings support the clinical utility of OGM in hematologic cancers, though no revenue, regulatory, or commercial adoption metrics were disclosed.